STOCK TITAN

BioSig Technologies Inc SEC Filings

BSGM Nasdaq

Welcome to our dedicated page for BioSig Technologies SEC filings (Ticker: BSGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The BSGM SEC filings archive on Stock Titan presents the regulatory record of the company formerly known as BioSig Technologies, Inc., which has since rebranded as Streamex Corp. and now trades under the symbol STEX. These documents trace the company’s transition from a medical device technology issuer to a business focused on real-world asset and gold tokenization.

Key filings include multiple Current Reports on Form 8-K detailing material events such as the merger with Streamex Exchange Corporation, the amendment to the certificate of incorporation changing the corporate name to Streamex Corp., and the Nasdaq ticker symbol change from BSGM to STEX. Other 8-K filings describe the secured convertible debenture purchase agreement with an institutional investor, the issuance of an initial tranche of convertible debentures, and related security and registration rights agreements.

The archive also contains a definitive proxy statement on Form DEF 14A for the company’s annual meeting, which outlines proposals including director elections, executive compensation advisory votes, auditor ratification, and amendments to the long-term incentive plan. Additional filings report amendments to the certificate of incorporation to increase authorized shares and to classify the board into staggered terms, as well as a tokenized yield partnership agreement related to precious-metal lease and bond programs.

On Stock Titan’s filings page, investors can review these historical BSGM documents alongside AI-powered summaries that explain the main terms, structures, and implications of each report. The feed updates as new Streamex Corp. (STEX) filings appear in the SEC’s EDGAR system, allowing users to follow the company’s ongoing regulatory disclosures, including future 10-K annual reports, 10-Q quarterly reports, and any Form 4 insider transaction filings associated with the successor entity.

Rhea-AI Summary

Streamex Corp. (STEX) director Morgan Lekstrom reported an indirect open-market purchase of the company’s common stock. On 11/21/2025, a total of 7,000 shares of common stock were acquired at a price of $3.58 per share, coded as a purchase transaction. After this trade, the reporting person is shown as beneficially owning 7,000 shares.

The filing states that these shares are held indirectly through All Mine Consulting Ltd., an entity over which the reporting person has voting and dispositive control. The Form 4 is filed as a single-reporting-person filing and reflects only non-derivative equity securities, with no derivative positions reported in Table II.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Streamex Corp. (STEX) reported that a director received a grant of 125,000 shares of common stock as a restricted stock award on November 18, 2025 under the company’s 2023 Equity Incentive Plan. The award was valued using a closing share price of $4.14 on the grant date and will vest in full on the one-year anniversary of that date. Following this grant, the director beneficially owns 228,345 shares of Streamex common stock, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Streamex Corp. is asking stockholders to vote at its virtual 2025 annual meeting on December 30, 2025. The ballot includes electing two Class I directors, advisory votes on executive pay and how often that vote should occur, ratifying CBIZ CPAs P.C. as auditor, approving a major increase to the 2023 Long-Term Incentive Plan, and a proposal to allow adjournment of the meeting if needed.

The plan amendment would raise the shares of common stock authorized for issuance under the plan by 22,494,324 shares, bringing the total to 37,230,130 shares. As of the November 7, 2025 record date, there were 39,228,103 shares of common stock outstanding, 105 shares of Series C Preferred Stock, and 109,070,079 Exchangeable Shares with voting rights similar to common stock. Common, preferred, and Super Voting Preferred Stock vote together as a single class. The board recommends voting “FOR” all six proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy
Rhea-AI Summary

Streamex Corp. is registering 27,885,987 shares of common stock for resale by existing holders. The shares consist mainly of up to 26,556,194 shares issuable upon conversion of two $25 million senior secured convertible debentures with Yorkville, plus 1,329,793 shares issuable on conversion of Exchangeable Shares from the Streamex acquisition. Streamex itself is not selling shares in this offering and will not receive proceeds from resales, though it previously received approximately $22.2 million in net proceeds from the first debenture, allocating $12.6 million into vaulted physical gold to support a gold-linked tokenization strategy. Shares outstanding were 148,610,687 as of November 17, 2025. The company reports large cumulative losses of about $294.1 million and auditors have raised substantial doubt about its ability to continue as a going concern, while the debentures and related registrations introduce significant potential dilution and stock overhang.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary

Streamex Corp. reported significant governance and leadership changes. Three directors — Steven Abelman, Christopher Baer and Anthony Amato — resigned effective immediately, each stating the decision was not due to any disagreement with the company. The board appointed Kevin Gopaul as an independent Class II director and member of all key committees, with an annual cash retainer of $40,000 plus $25,000 for each committee under the current policy.

The company entered new agreements with its top leaders. Chief Executive Officer Karl Henry McPhie will receive a $225,000 base salary, a target bonus equal to 65% of salary, and, subject to stockholder approval, 100,000 fully vested shares and 900,000 restricted stock units vesting over four years, along with double-trigger severance and equity acceleration protections. Chief Financial Officer Ferdinand Groenewald will receive the same base salary, a 65% target incentive mix of cash and equity, and, subject to stockholder approval, 100,000 shares and 400,000 RSUs, with tiered severance and COBRA benefits.

Chairman Morgan Lekstrom entered a Chairman Agreement providing a $40,000 board retainer, a $99,000 chairman retainer, and 100,000 shares vesting over one year subject to stockholder approval. Separately, a charter amendment created a classified board structure with directors divided into three staggered classes, setting multi‑year terms for Lekstrom, McPhie, Gopaul and Donald Browne.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Streamex Corp. (Nasdaq: STEX) filed its Q3 report, reflecting a transformative acquisition and a materially weaker balance sheet. Total assets rose to $130.5 million, driven by $69.9 million of goodwill and $45.4 million of intangible assets from the May 28 acquisition of Streamex Exchange. Cash increased to $11.0 million, but the company posted no revenue for Q3 and the year-to-date period.

The quarter showed a net loss of $15.6 million (Q3) and $38.8 million (nine months), as operating expenses and a $10.2 million loss from remeasuring a derivative liability weighed on results. Current liabilities surged to $125.6 million, including a $115.7 million derivative liability tied to exchangeable shares issued in the acquisition, leading to a stockholders’ deficit of $(6.9) million. Management disclosed substantial doubt about continuing as a going concern due to a $111 million working capital deficit and operating cash use of $7.4 million.

As a subsequent event, on November 4, 2025 shareholders approved lifting the 19.99% cap on conversions, allowing exchangeable shares to convert into common stock and triggering reclassification of the derivative liability to equity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
Rhea-AI Summary

Streamex Corp. (BSGM) entered a financing and issued a secured convertible debenture. On November 4, 2025, the company closed an initial tranche with a principal amount of $25,000,000, delivering approximately $24,000,000 in gross proceeds. The debenture matures on November 4, 2027 and bears 4.00% interest, increasing to 18.00% upon an event of default.

The investor may convert principal and accrued interest at the lower of a fixed price of $6.016 per share (subject to a one-time downward reset tied to post-effectiveness VWAP) or 97.0% of the lowest daily VWAP during the three trading days before conversion, with a $4.00 per-share floor. A 4.99% beneficial ownership cap applies. The company may prepay with a 10% premium, and the debenture is secured by U.S. and Canadian guarantees and security agreements.

Directors, officers, and certain shareholders agreed to 180-day lock-ups. Streamex agreed to register the resale of conversion shares under a registration rights agreement. Yorkville may purchase a second $25,000,000 debenture upon conditions and additional debentures up to $50,000,000 upon mutual agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Streamex Corp. (formerly BioSig Technologies) announced that stockholders approved the Acquisition Proposal to issue approximately 109,070,079 shares of common stock and one share of Super Voting Preferred Stock under the Share Purchase Agreement dated May 23, 2025, as amended. The proposal passed with 16,386,371 votes for, 267,215 against, and 27,673 abstentions. The company stated the acquisition of Streamex Exchange Corporation has closed.

The vote occurred at a reconvened special meeting on November 4, 2025. The company also furnished an investor presentation as Exhibit 99.1 under Regulation FD, which is not deemed filed. Streamex’s common stock trades on Nasdaq under the symbol STEX.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Streamex Corp. announced Nasdaq’s formal approval for the continued listing of its common stock on the Nasdaq Capital Market under the ticker STEX.

The company also set a reconvened special meeting of stockholders to vote on Proposal 1 – the Acquisition Proposal at 3:00 p.m. Eastern Time on November 4, 2025. The meeting will be held via webcast at www.virtualshareholdermeeting.com/BSGM2025SM, and stockholders of record as of the applicable record date may attend, vote, and ask questions online.

The disclosure was furnished under Regulation FD, with additional details provided in an accompanying press release (Exhibit 99.1).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Streamex Corp. entered a Second Amendment to its Secured Convertible Debenture Purchase Agreement with Yorkville, supporting a program for up to $100,000,000 in convertible debentures. The company plans to issue a $25,000,000 first convertible debenture that matures in 24 months and bears 4.00% interest, rising to 18.00% upon default. Closing is conditioned on maintaining Nasdaq listing approval.

The debenture is convertible at the lower of a fixed price set at 125% of the VWAP prior to first closing (with a one‑time downward reset tied to the Resale Registration Statement’s effectiveness window) or 97.0% of the lowest daily VWAP over the prior three trading days, with a $4.00 floor, subject to anti‑dilution adjustments and a 19.99% cap under Nasdaq rules. At least $25.1 million of proceeds—$12.6 million at first closing and $12.5 million at second closing—must be deposited to purchase Allocated Vaulted Gold Bullion as collateral. Obligations are secured by a first‑priority lien on substantially all assets. The securities will be issued in reliance on Section 4(a)(2) and/or Regulation D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of BioSig Technologies (BSGM)?

The current stock price of BioSig Technologies (BSGM) is $6.1 as of September 11, 2025.

What is the market cap of BioSig Technologies (BSGM)?

The market cap of BioSig Technologies (BSGM) is approximately 157.0M.

BSGM Rankings

BSGM Stock Data

156.96M
25.09M
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
WESTPORT

BSGM RSS Feed